<DOC>
	<DOCNO>NCT00983853</DOCNO>
	<brief_summary>The purpose study determine whether combination telaprevir , peginterferon alfa-2a , ribavirin safe effective treat hepatitis C virus ( HCV ) infection subject infect HCV human immunodeficiency virus ( HIV ) .</brief_summary>
	<brief_title>Safety Efficacy Telaprevir Combination With Peginterferon Alfa-2a Ribavirin Subjects Co-Infected With Hepatitis C Virus ( HCV ) HIV</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic , genotype 1 , hepatitis C detectable HCV RNA HIV1 infection &gt; 6 month Documentation liver biopsy within 1 year screen visit show evidence hepatitis ( demonstrated inflammation and/or fibrosis ) Previous treatment approve investigational drug drug regimen treatment hepatitis C Previous treatment interferon ribavirin Evidence hepatic decompensation cirrhotic subject Subjects participate clinical study involve administration investigational drug within 2 month Part A : subject HAART regimen within 12 week study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>VX-950</keyword>
	<keyword>INCIVEK</keyword>
	<keyword>INCIVO</keyword>
</DOC>